TerminatedPhase 2NCT00832507
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gilead Sciences
- Principal Investigator
- Gennyne Walker, PhDSenior Clinical Research Scientist, Gilead Sciences
- Intervention
- Cicletanine(drug)
- Enrollment
- 162 enrolled
- Eligibility
- 16-70 years · All sexes
- Timeline
- 2009 – 2012
Study locations (30)
- University of South Alabama, Mobile, Alabama, United States
- Arizona Pulmonary Specialists, Phoenix, Arizona, United States
- VA Greater LA Healthcare System, Los Angeles, California, United States
- University of California San Diego Medical Center, San Diego, California, United States
- Harish H. K. Murthy, MD, San Jose, California, United States
- UCLA Medical Center, Torrance, California, United States
- University of Colorado Denver, Aurora, Colorado, United States
- University of Connecticut Health Center, Farmington, Connecticut, United States
- Cleveland Clinic, Fort Lauderdale, Florida, United States
- University of Florida, Gainesville, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Medical College of Georgia, Augusta, Georgia, United States
- University of Chicago Hospital, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- Louisiana State University, New Orleans, Louisiana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00832507 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
- RECRUITINGPHASE2NCT06351345129 Xenon Imaging in Patients Treated With SotaterceptBastiaan Driehuys
- RECRUITINGPHASE4NCT07140484Sotatercept in Pulmonary Arterial HypertensionUniversity of Alberta
- RECRUITINGPHASE2NCT07175038A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)AllRock Bio, Inc.
- RECRUITINGNCT07013149The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial HypertensionUniversity of Sao Paulo General Hospital
- RECRUITINGNCT06998329PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArchUniversity of Sao Paulo General Hospital
- ENROLLING BY INVITATIONPHASE2NCT06992440Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial HypertensionGustavo A Heresi, MD, MS
- RECRUITINGNANCT06968962Comparison of Sequential to Initial Combination Therapy in PAHSecond Affiliated Hospital, School of Medicine, Zhejiang University
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →